

UNIVERSITY OF PENNSYLVANIA - SCHOOL OF MEDICINE
Curriculum Vitae

September 2005

Timothy Richard Rebbeck, Ph.D.

Office Address: Center for Clinical Epidemiology and Biostatistics
University of Pennsylvania School of Medicine
904 Blockley Hall, 423 Guardian Drive
Philadelphia, PA 19104-6021
Phone: 215-898-1793, Fax: 215-573-2265
Email: trebbeck@cceb.med.upenn.edu

Laboratory Address: 531 Biomedical Research Building II/III
421 Curie Boulevard
Philadelphia, PA 19104-6142
Phone: 215-573-4526
Fax: 215-573-7602

Education:

1980-84	B.A.	Northwestern University (Biology)
1984-86	Sc.M.	The Johns Hopkins University (Epidemiology)
1986-91	A.M.	The University of Michigan (Statistics)
1986-91	Ph.D.	The University of Michigan (Human Genetics)

Postgraduate Training and Fellowship Appointments:

1991-93 Postdoctoral Associate, Institute for Cancer Research, Fox Chase
Cancer Center, Philadelphia, PA.

Military Service: None

Faculty Appointments:

1993-94 Assistant Member, Institute for Cancer Research, Fox Chase Cancer
Center, Philadelphia.

1994-95 Assistant Research Professor of Epidemiology in Medicine,
Department of Medicine, University of Pennsylvania School of
Medicine, Philadelphia.

1995-99 Assistant Professor of Epidemiology, University of Pennsylvania
School of Medicine, Philadelphia.

1999-04 Associate Professor of Epidemiology, Department of Biostatistics and
Epidemiology, University of Pennsylvania School of Medicine.

2004- Professor of Epidemiology, Department of Biostatistics and
Epidemiology, University of Pennsylvania School of Medicine.

Hospital and Administrative Appointments:

1994- Senior Scholar, Center for Clinical Epidemiology and Biostatistics,
University of Pennsylvania School of Medicine, Philadelphia.

1994- Member, University of Pennsylvania Abramson Cancer Center.
 1999- Cancer Epidemiology and Risk Reduction Program Leader/co-Leader,
 University of Pennsylvania Abramson Cancer Center.
 2004- Director, Center for Genetics and Complex Traits, University of
 Pennsylvania School of Medicine, Philadelphia.

Specialty Certification: None

Licensures: None

Awards, Honors, and Membership in Honorary Societies:

1983 Richter Scholar (Northwestern University).
 1984 Sigma Xi Research Award.
 1984 Sigma Xi.
 1986-89 National Institutes of Health Predoctoral Genetics Training Fellowship.

 1990 Hispanic, Asian, and Native American (HANA) Fellowship.
 1992-93 National Cancer Institute Cancer Prevention and Control Research
 Fellowship.
 1998 Association for the Cure of Cancer of the Prostate (CaPCURE)
 Prostate Cancer Research Award.

Memberships in Professional and Scientific Societies:

National and International Societies:

1988- American Society of Human Genetics.
 1991- International Genetic Epidemiology Society.
 1993- American Society of Preventive Oncology.
 1996- American Association for Cancer Research.
 (Steering Committee, Molecular Epidemiology Group, 1999-2004)
 (Annual Meeting Program Committee, 2000-2001, 2002-2003)
 (Teller's Committee, 2000-2001)
 (Chair-Elect/Chair, Molecular Epidemiology Group, 2001-2003)
 (Awards Committee, 2002-2003)
 (Special Conferences Committee, 2002-2005)

Local Societies: None

National and International Scientific Committees:

1995 Grant Reviewer, National Action Plan on Breast Cancer.
 1996-1997 Grant Reviewer, California Breast Cancer Research Program.
 1996 Grant Reviewer, Henry Ford Health System Institutional Research Fund.
 1996-2002 Grant Reviewer, NIH Epidemiology and Disease Control-2 Study Section.
 1997 Grant Reviewer, California Tobacco-Related Disease Research Program.
 1997 Veteran's Administration Merit Review Board.
 1998, 2002 National Cancer Institute Parent Committee E.
 2000 Grant Reviewer, U.S. Army Breast Cancer Grant Program.
 2000 Grant Reviewer, U.S. Army Breast Cancer Grant Program.
 2001- California Teacher's Study External Advisory Committee.
 2001 NCI Gynecologic Oncology Progress Review Group.

- 2001- Northeast Regional Cancer Institute Scientific Advisory Board.
 2001- 50 Hoops National Advisory Board.
 2002 Grant Reviewer, Genome Canada.
 2002- American Cancer Society Biological Specimen Advisory Panel, Atlanta, GA.
 2002- New York University Women's Health Study External Advisory Board, New York.
 2003 Grant Reviewer, Breast Cancer Research Foundation of Canada.
 2003 D.W. Reynolds Foundation Cardiovascular Clinical Research Center Peer Review Committee, Miami, FL.
 2003- United States Representative, International Hereditary Cancer Center.
 2004 National Cancer Advisory Board Subcommittee on the Development of a National Biotechnology Initiative for Cancer, Bethesda, MD.
 2003- Barbados National Cancer Study Scientific Advisory Board.
 2003- University of Puerto Rico-Roswell Park Cancer Institute Cancer Research Partnership External Advisory Committee, Buffalo, NY and San Juan, PR.
 2004- National Human Genome Research Institute Social and Behavioral Research Branch Scientific Advisory Board, Bethesda, MD.
 2004- External Advisory Board Member, Braman Family Breast Cancer Research Institute, University of Miami Sylvester Comprehensive Cancer Center, Miami.
 2004-09 Board of Scientific Counselors, National Cancer Institute.
 2005 College of Reviewers for the Canada Research Chairs Program, Ottawa, Canada.
 2005- External Advisory Board Member, FORCE: Facing Our Risk of Cancer Empowered.

Local Scientific Committees: None

Editorial and Review Positions:

- 1991- Editorial Consultant, *Genetic Epidemiology, American Journal of Human Genetics, Nature Genetics, Journal of the National Cancer Institute, Human Heredity, Cancer Epidemiology Biomarkers and Prevention, Clinical Cancer Research, Cancer Research, International Journal of Cancer, Breast Cancer Research and Treatment, Cancer Letters, Annals of Internal Medicine, Journal of Clinical Oncology, New England Journal of Medicine*, and others.
 1997-03 Statistical Editor, *Journal of the National Cancer Institute*.
 1999-04 Associate Editor, *Cancer Epidemiology, Biomarkers and Prevention*.
 2003- Associate Editor, *Journal of the National Cancer Institute*.
 2003- Editorial Board, *Hereditary Cancer in Clinical Practice*.
 2003- Associate Editor, *International Journal of Cancer Prevention*.
 2004- Senior Editor, *Cancer Epidemiology, Biomarkers and Prevention*.

Academic Committees at the University of Pennsylvania and Affiliated Hospitals:

- 1996-97 Member, Committee to Review the Department of Radiation Oncology.

- 1996-02 Member, Hereditary Cancer Program Advisory Board of The Northeast Regional Cancer Institute, Scranton, PA.
- 1998- Member, Cancer Genetics Steering Committee.
- 1998- Member, Clinical Trials Scientific Review and Monitoring Committee.
- 1999-01 Member, Medical Faculty Senate Steering Committee.
- 1999-00 Member, Committee to Review the Department of Genetics.
- 2000-02 Chair, Strategic Planning Committee, Center for Clinical Epidemiology and Biostatistics.
- 2000-04 Chair, Web Committee, Center for Clinical Epidemiology and Biostatistics.
- 2000- Member, Committee on Appointments and Promotions, Department of Biostatistics and Epidemiology.
- 2002 Member, Genetics Committee, Research Coordinating Council.
- 2002- Member, Biostatistics Faculty Search Committee.
- 2002- Chair, Genetic Epidemiology/Statistical Genetics Faculty Search Committee.
- 2004-05 Member, Department of Genetics Chair Search Committee.
- 2004- Member, Council on Health Promotion and Disease Prevention.
- 2004- Member, Robert Wood Johnson Health and Society Scholar Steering Committee.
- 2005- Member, Committee on Appointments and Promotions, University of Pennsylvania School of Medicine.

Major Teaching Responsibilities at the University of Pennsylvania and Affiliated Hospitals:

- 1995- Primary MSCE Mentor and Thesis Chair, Biostatistics and Epidemiology Graduate Group (Charambolos Andreadis, Danielle Antin-Ozerkis, Christina Bandera, M. Anne Blackwood-Chirchir, Anne Deitz, Thornton A. Mason, Hanna Renert, Ilene Rosen, Pedro Sanchez, Anil Vachani).
- 1999- Doctoral Dissertation Chair, Biostatistics and Epidemiology Graduate Group (Richard Aplenc, Jason Christie, Yiting Wang)
- 1997- Doctoral Dissertation Committee Member (Karen Brown, Cheryl Clarkin, David Margolis, Leilah McNabb, Susan Nolte).
- 1996-99 Course Director, "Cancer Epidemiology and Prevention" (BE642), Spring Semester.
- 1999- Human Genetics Training Track Leader, Center for Clinical Epidemiology and Biostatistics.
- 1998- Course Director, "Introduction to Genetic Epidemiology" (EP575).
- 2000- Course Director, "Methods in Genetic Epidemiology" (EP675).
- 2002- Course Director, "Advanced Topics in Genetic Epidemiology" (EP775).

Selected Lectures by Invitation:

- March 31, 1998 "Modification of Breast Cancer Risk in *BRCA1* Mutation Carriers by the Androgen Receptor CAG Repeat Polymorphism", American Association for Cancer Research Annual Meeting, New Orleans, LA.

- March 31, 1998 Moderator: "Genetic Susceptibility to Cancer Minisymposium", American Association for Cancer Research Annual Meeting, New Orleans, LA.
- May 16, 1998 "Understanding the Role of Genes in Commonly Occurring Cancers", New Jersey Academy of Family Physicians, Philadelphia.
- May 21, 1998 "Molecular Epidemiology of Human Cancer Susceptibility", Genetic Toxicology Association, Newark, DE.
- June 26, 1998 "Epidemiologic and Molecular Foundation of Breast and Ovarian Genetic Susceptibility", American Cancer Society Second National Conference on Cancer Genetics, San Francisco, CA.
- September 13, 1998 "Genetic Modification of *BRCA1*-Associated Cancer Penetrance". European Breast Cancer Linkage Consortium, Dublin, Ireland.
- October 31, 1998 "Cancer Risk Reduction by Prophylactic Surgery in *BRCA1* and *BRCA2* Mutation Carriers", 48th Annual Meeting of the American Society of Human Genetics, Denver, CO.
- November 4, 1998 "Molecular Markers of Breast Carcinogenesis", UICC International Symposium - Workshop on Epidemiology and Prevention of Cancer, Bangkok, Thailand.
- December 18, 1998 "Breast Cancer Risk Modification in *BRCA1* Mutation Carriers", Memorial Sloan-Kettering Institute, New York, NY.
- December 21, 1998 "Breast Cancer Risk Modification in *BRCA1* Mutation Carriers", The Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD.
- April 14, 1999 "Modification of Breast Cancer Risk by in *BRCA1* mutation carriers by the *AIB1* gene". American Association for Cancer Research Annual Meeting, Philadelphia, PA.
- May 15-16, 1999 "Hereditary Breast Cancer Risk and Risk Modification", American Society of Clinical Oncology Annual Meeting, Atlanta.
- September 2, 1999 "Prediction and Modification of *BRCA1*-Associated Cancers", Mayo Clinic, Rochester, MN.
- September 23, 1999 "*BRCA1*, *BRCA2*, and Breast Cancer Risk", Boston University, Boston, MA.
- September 29, 1999 "Genetic Epidemiology", 21st Annual Conference of the International Association of Cancer Registrars, Lisbon, Portugal.
- March 13, 2000 "Risk prediction and Modification of *BRCA1* and *BRCA2*-Associated Cancers". "Genes and Environment" Clues to Cancer Causation and Prevention" Conference, San Diego, CA.
- April 1, 2000 "Molecular Epidemiology: 'Functional Genomics' in Human Populations", American Association for Cancer Research Annual Meeting, San Francisco, CA.
- April 10, 2000 "Molecular Epidemiology of Cancer Predisposition: Example of *CYP3A4*", Environmental Mutagen Society Annual Meeting, New Orleans, LA.
- May 22, 2000 "Prophylactic Oophorectomy and Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers", American Society of Clinical Oncology Annual Meeting, New Orleans, LA.
- September 21, 2000 "Molecular Epidemiology of Melanoma", Second Annual Wallace Clark Symposium, Philadelphia, PA.

- October 6, 2000 "Genetics and Breast Cancer", Perspectives in Breast Cancer 2000, Washington, DC.
- October 21, 2000 "High Risk Populations and Cancer Prevention", Psychosocial Approaches to Cancer Prevention Conference, Philadelphia.
- November 8-9, 2000 "*BRCA1/2* Risk Modifiers". Community and International Perspectives on Cancer Genetics Colaborative Research Conference, Houston, TX.
- November 21, 2000 "Prediction and Modification of Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers", University of Chicago, Chicago, IL.
- December 14, 2000 "Prediction and Modification of Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers", Fred Hutchinson Cancer Research Center, Seattle.
- April 6, 2001 "Framework for Selection of Candidate Genes for Association Studies", NIH Workshop on Genetic Susceptibility to Prostate Cancer, Columbia, MD.
- September 25, 2001 "Inherited Predisposition to Breast Cancer", EMS Conference on Breast Cancer and Environmental Mutagens: Bridging Molecular Research to Medicine and Public Health, Research Triangle Park, NC.
- November 14-17, 2001 Relevance of Biomarkers for the Study of Toxicological Impact of Exposures on Carcinogenesis". Workshop on Mechanistic Considerations in the Design and Interpretation of Molecular Epidemiologic Studies of Cancer, IARC, Lyon, France.
- November 29, 2001 "Bilateral Oophorectomy for *BRCA1* Carriers?". Endocrine Treatment and Prevention of Gynecologic and Breast Cancers Conference, Brussels, Belgium.
- December 11, 2001 "Susceptibility Biomarkers in Cancer Etiology", Cancer Cubed Symposium, Washington, DC.
- January 25, 2002 "Prediction and Modification of Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers", Moffitt Cancer Center, Orlando, FL.
- March 19, 2002 "Contribution of Inherited Susceptibility to Prostate Cancer", Distinguished Lecturer in Cancer Genetics, Siteman Cancer Center, Washington University, St. Louis, MO.
- October 14, 2002 "Methodologic Approaches for Application of Pharmacogenetics to Cancer Prevention", AACR Special Conference: Frontiers in Cancer Prevention Research. Boston, MA.
- September 26, 2002 "Molecular Epidemiology of Cancer", American Cancer Society, Atlanta, GA.
- November 8, 2002 "Molecular Epidemiology of Prostate Cancer", Prout's Neck Prostate Cancer Meeting, Prout's Neck, ME.
- November 12, 2002 "Design and Analysis Considerations for Genotype-Disease Association Studies", American Public Health Association, Philadelphia, PA.
- January 16, 2003 "Modifiers of Cancer Risk in *BRCA1/2* Mutation Carriers", Cancer Family Registries Breast Scientific Conference, Kona, HI.
- January 18, 2003 "Efficient Approaches for Complex Interactions", International Symposium: Molecular and Genetic Epidemiology of Cancer, Kona, HI.
- February 2, 2003 "*MC1R* Genotype in Human Pigmentation and Melanoma Risk", Genes, Environment, and Melanoma Conference, Whistler, BC.

- March 11, 2003 “Prediction and Modification of Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers”, American Society of Preventive Oncology Annual Meeting, Philadelphia, PA.
- April 4, 2003 “Modifiers of Hereditary Cancer Risk”, Invited Speaker and Session Chair, American Association for Cancer Research Annual Meeting, Toronto, ON.
- April 29, 2003 “Ethnic Variability in Prostate Cancer Risk”, Howard University, Washington, DC.
- May 2, 2003 “Genotype Association Studied: Are We Learning What We're Supposed To?”, M.D. Anderson Cancer Center, Houston.
- June 2, 2003 “Gene-Environment Interactions in *BRCA1/2*-Associated Breast Cancer”, Breast Cancer Linkage Consortium Meeting, Madrid, Spain.
- June 22, 2003 “Pigmentation Genotypes and Phenotypes in Melanoma Etiology”, First International Melanoma Research Congress, Philadelphia, PA.
- September 6, 2003 “New Approaches in Molecular Epidemiology”, American College of Epidemiology Annual Scientific Sessions, Chicago, IL.
- September 13, 2003 “Current Paradigms for SNP Studies” (Chair), AACR Special Conference on SNP's, Haplotypes, and Cancer: Applications in Molecular Epidemiology, Key Biscayne, FL.
- October 21, 2003 “Prediction and Modification of Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers”, Department of Epidemiology, University of Minnesota, Minneapolis, MN.
- October 28, 2003 “*In silico* Approaches to Functional Significance of SNPs in Molecular Epidemiology”, Frontiers in Cancer Prevention Research, Phoenix, AZ.
- November 5, 2003 “SNPs Influencing Cancer Risks”, American Society of Human Genetics Annual Meeting, Los Angeles, CA.
- December 4, 2003 “Current Status and Needs of Haplotype-Based Cancer Research in Human Populations”, NCI-Sponsored Workshop “Linking Haplotypes and Genetic Variation With Cancer Risk Assessment, Detection, Prevention, and Treatment”, Bethesda, MD.
- January 29, 2004 “Prediction and Modification of Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers”, Duke University, Durham, NC.
- February 11, 2004 “Molecular Epidemiology of Prostate Cancer”, University of Texas Health Sciences Center, San Antonio.
- February 13, 2004 “Race, Genetics, and Disease”, Centers for Population Health and Health Disparities Annual Meeting, Galveston, TX.
- February 25, 2004 “Genetics of Common Cancer Risk”, New York University School of Medicine, New York, NY.
- April 27, 2004 “Prostate Cancer in Africans and African Americans”, Cheik Anta Diop University, Dakar, Senegal.
- September 9, 2004 “The Contribution of Molecular Epidemiology to Our Understanding of Human Cancer After the Human Genome”, Roswell Park Cancer Center Annual Scientific Symposium, Buffalo, NY
- September 21, 2004 “New Approaches for Prostate Cancer Gene Discovery”, Conference on Prostate Cancer Disparities: Science, Health Care, and Public Policy. Washington, DC.

- October 3, 2004 "Genetic and Environmental Modifiers of Cancer Penetrance in *BRCA1* and *BRCA2* Mutation Carriers". Environmental Mutagen Society 35th Annual Meeting, Pittsburgh, PA.
- October 16, 2004 "Population Approaches for Genotype and Haplotype Association Studies", American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, Seattle, WA.
- October 28, 2004 "After the Genome Project: Making Sense of Genetic Variation in Human Disease", Pennsylvania State University Cancer Center Annual Scientific Symposium, Hershey, PA.
- December 7, 2004 "Novel Approaches to Human Gene Discovery", M.D. Anderson Cancer Center Day of Science, Houston, TX.
- January 28, 2005 "Approaches for Human Cancer Gene Discovery", Hematology/Oncology Grand Rounds, Henry Ford Health System, Detroit, MI.
- February 10, 2005 "Pigmentation Genetics and Melanoma Susceptibility", Department of Medicine Grand Rounds, University of New Mexico Cancer Center, Albuquerque, NM.
- February 17, 2005 "After the Human Genome Project: Epidemiologic Approaches to Human Cancer Gene Discovery". American Association for the Advancement of Science Symposium, Washington, DC.
- April 18, 2005 "Population Stratification: Trivial Pursuit or Serious Concern?", American Association for Cancer Research Annual Meeting, Anaheim, CA.
- May 3, 2005 "Cancer Gene Identification in the Post-Genome Era", Yale University Cancer Center Grand Rounds, New Haven, CT.
- May 13, 2005 "Modifiers of Cancer Risk in *BRCA1/2* Mutation Carriers". American Society for Clinical Oncology Annual Meeting, Orlando, FL.
- June 9, 2005 "Prediction and Modification of Cancer Risk in *BRCA1/2* Mutation Carriers" Era of Hope Meeting for the Department of Defense Breast Cancer Research Program, Philadelphia, PA.
- September 10, 2005 "New Genetic and Molecular Markers for Melanoma: What are they and What is Their Value?". The 6th World Congress on Melanoma, Vancouver, BC.
- November 14, 2005 "Genetics and Prostate Cancer". African Organization for Research and Treatment in Cancer (AORTIC) Meeting, Dakar, Senegal.

Organizing Roles in National and International Scientific Meetings

- April 6, 2001 Co-Chair: NIH Workshop on Genetic Susceptibility to Prostate Cancer, Columbia, MD.
- March 24-28, 2001 Program Committee, American Association for Cancer Research Annual Meeting, New Orleans.
- April 4-9, 2003 Program Committee, American Association for Cancer Research Annual Meeting, Toronto.
- September 13-17, 2003 Co-Chair: Special Conference of the American Association for Cancer Research "SNPs, Haplotypes and Cancer: Applications in Molecular Epidemiology", Key Biscayne, FL.
- October 26-30, 2003 Scientific Committee: American Association for Cancer Research International Conference "Frontiers in Cancer Prevention Research", Phoenix, AZ.

- Oct. 30–Nov. 2, 2005 Scientific Committee: American Association for Cancer Research International Conference “Frontiers in Cancer Prevention Research”, Baltimore, MD.
- November 14-16, 2005 Scientific Conference Co-Chair: Cancer in Africa: A Call to Action. Bi-annual Meeting of the African Organisation for Research and Training. Dakar, Senegal.
- January 11-16, 2006 Scientific Program Committee: Special Conference of the American Association for Cancer Research “New Developments in the Prediction of Prognosis after a Diagnosis of Cancer”, Charleston, SC.

Bibliography:

Research Publications, Peer Reviewed:

1. Rebbeck TR, Turner ST, Michels VV, Moll PP (1991) Genetic and Environmental Explanations for the Distribution of Sodium-Lithium Countertransport in Pedigrees from Rochester, MN. *American Journal of Human Genetics*, 48(6):1092-1104.
2. Turner ST, Rebbeck TR, Sing CF (1992) Sodium-Lithium Countertransport and Probability of Hypertension in Caucasians 47 to 89 Years Old. *Hypertension*, 20(6):841-850.
3. Rebbeck TR, Dietz FR, Murray JC, Buetow KH (1993) A Single Gene Explanation for the Probability of Having Idiopathic *Talipes Equinovarus*. *American Journal of Human Genetics*, 53:1051-1063.
4. Rebbeck TR, Turner ST, Sing CF (1993) Sodium-Lithium Countertransport Genotype and Probability of Having Hypertension in Adults Ages 20-89 in Rochester, MN. *Hypertension*, 22(4):560-568.
5. Rebbeck TR, Rosvold EA, Duggan DJ, Zhang J, Buetow KH (1994) Genetics of *CYP1A1*: Co-Amplification of Specific Alleles by Polymerase Chain Reaction and Association with Breast Cancer. *Cancer Epidemiology, Biomarkers, and Prevention*, 3:511-514.
6. Rebbeck TR, Lustbader ED, Buetow KH (1994) Somatic Allele Loss in Genetic Linkage Analysis of Cancer. *Genetic Epidemiology*, 11:419-429.
7. Schnur RE, Wick PA, Bailey C, Rebbeck TR, Weleber RG, Wagstaff J, Grix AW, Pagon RA, Hockey A, Edwards MJ (1994) Phenotypic Variability in X-Linked Ocular Albinism and its Relationship to Linkage Genotypes. *American Journal of Human Genetics*, 55(3):484-496.
8. Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL (1995). Assessment and Counseling for Breast Cancer Risk: A Guide for Clinicians. *Journal of the American Medical Association*, 273(7):577-585.
9. Lustbader ED, Rebbeck TR, Buetow KH (1995) Using Loss of Heterozygosity Data in Affected Pedigree Member Linkage Tests. *Genetic Epidemiology*, 12:339-350.
10. Rogatko A, Rebbeck TR, Zacks S (1995) Risk Prediction with Linked Markers: Pedigree Analysis. *American Journal of Medical Genetics*, 59:24-32.
11. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ruttledge MH, Larsson C, Goldgar DE, Narod SA (1996) Ovarian Cancer Risk in *BRCA1* Carriers is Modified by the *HRAS1* Variable Number of Tandem Repeats (VNTR) Locus. *Nature Genetics*, 12:309-311.

12. Pellegrino JE, Rebbeck TR, Brown MJ, Bird TD, Chance PF (1996) Mapping of Hereditary Neuralgic Amyotrophy (Familial Brachial Plexus Neuropathy) to Distal Chromosome 17q. *Neurology*, 46:1128-1132.
13. Maris JM, Kyemba SM, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Yanofsky RA, Feldman GL, Brodeur GM (1996) Familial Predisposition to Neuroblastoma Does Not Map to Chromosome Band 1p36. *Cancer Research*, 56(15):3421-3425.
14. Rebbeck TR, Turner ST, Sing CF (1996) Probability of Hypertension: Effects of Sex, History of Hypertension in Parents, and Other Risk Factors. *Journal of Clinical Epidemiology*, 49(7):727-734.
15. Rebbeck TR, Couch FJ, Kant J, Calzone K, DeShano M, Garber JE, Weber BL (1996). Genetic Heterogeneity in Hereditary Breast Cancer: Role of *BRCA1* and *BRCA2*. *American Journal of Human Genetics*, 59:547-553.
16. Tonin P, Weber B, Offit K, Couch F, Rebbeck TR, Neuhausen S, Godwin A, Daly M, Wagner-Costalos J, Berman D, Grana G, Fox E, Kane MF, Kolodner RD, Krainer M, Haber DA, Struewing JP, Warner E, Rosen B, Lerman C, Peshkin B, Norton L, Serova O, Foulkes W, Lynch HT, Lenoir GM, Narod SA, Garber JE (1996) Frequency of Recurrent *BRCA1* and *BRCA2* Mutations in 222 Ashkenazi Jewish Breast Cancer Families. *Nature Medicine*, 2(11):1179-1183.
17. Rebbeck TR, Godwin AK, Buetow KH (1996) Variability in Loss of Constitutional Heterozygosity Across Loci and Among Individuals: Association with Candidate Genes in Ductal Breast Carcinoma. *Molecular Carcinogenesis*, 17:117-125.
18. Rebbeck TR, Jordan HA, Schnur RA, Rogatko A (1997) Utility of Linked Markers in Genetic Counseling: Estimating Genetic Carrier Risks in X-Linked Ocular Albinism. *American Journal of Medical Genetics*, 70(1):58-66.
19. Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer JE, Campeau L, Ganguly A, Jablon L, Cobleigh MA, Hoskins K, Garber JE, Rebbeck TR, Weber BL (1997) A Predicted Probability Model for Presence of Germline *BRCA1* Mutations in Breast Cancer Families. *New England Journal of Medicine*, 336(20):1409-1415.
20. Rebbeck TR (1997) Molecular Epidemiology of the Human Glutathione-S-Transferase Genotypes *GSTM1* and *GSTT1* in Cancer Susceptibility. *Cancer Epidemiology, Biomarkers and Prevention*, 6:733-743.
21. Maris JM, Kyemba S, Rebbeck TR, White PS, Sulman EP, Jensen SJ, Allen C, Biegel JA, Brodeur GM (1997) Molecular Genetic Analysis of Familial Neuroblastoma. *European Journal of Cancer*, 33(12):1923-1928.
22. Pellegrino JE, George RAV, Biegel J, Farlow MR, Gardner K, Caress J, Brown MJ, Rebbeck TR, Bird TD, Chance PF (1997) Hereditary Neuralgic Amyotrophy: Evidence for Genetic Homogeneity and Refined Mapping to Chromosome 17q25. *Human Genetics*, 101(3): 277-283.
23. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber BL, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Aarason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkadottir R, Eyfjord J, Lynch H, Ponder B, Birch JM, Lindblom A, Stoppa-Lyonnet D, Bignon Y, Borg A, Hamman U, Haites N, Scott R, Maugard-Louboutin A, and The Breast Cancer Linkage Consortium (1998). Genetic Heterogeneity and Penetrance Analysis of the *BRCA1* and *BRCA2* Genes in Breast Cancer Families. *American Journal of Human Genetics*, 62(3):676-689.

24. Rebbeck TR, Rogatko A, Viana MAG (1998). Translation of Genetic Information from Laboratory to Clinic: Use of *BRCA1*, *BRCA2*, and *N-Acetyl Transferase-2* Genotypes in Breast Cancer Risk Evaluation. *Genetic Testing*, 1(3):157-164.
25. Brunet JS, Ghadirian P, Rebbeck TR, Lerman C, Garber JE, Tonin P, Abrahamson J, Foulkes WD, Daly MB, Wagner-Costalas J, Godwin A, Olopade F, Moslehi R, Liede A, Futreal A, Weber BL, Lenoir GM, Lynch HT, Narod SA (1998) The Effect of Smoking on Breast Cancer in *BRCA1* and *BRCA2* Carriers. *Journal of the National Cancer Institute*, 90(10):761-766.
26. Rubin SC, Blackwood MA, Bandera C, Behbakht K, Benjamin I, Rebbeck TR, Boyd J (1998). *BRCA1*, *BRCA2*, and HNPCC Gene Mutations in an Unselected Ovarian Cancer Population: Relationship to Family History and Implications for Genetic Testing. *American Journal of Obstetrics and Gynecology*, 178(4):670-677.
27. Felix CA, Hosler MR, Slater DJ, Parker RI, Masterson M, Whitlock JA, Rebbeck TR, Nowell PC, Lange BJ (1998) MLL Genomic Breakpoint Distribution within the Breakpoint Cluster Region in De Novo Leukemia in Children. *Journal of Pediatric Hematology and Oncology*, 20(4):299-308.
28. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R, Runnebaum IB (1998) p53 Germline Polymorphisms are Associated with an Increased Risk for Breast Cancer in German Women. *Anticancer Research*, 18:2095-2100.
29. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of Clinical Characteristics of Prostate Cancers by *CYP3A4* Genotype. *Journal of the National Cancer Institute*, 90(16):1225-1229.
30. Viana MG, Rogatko A, Rebbeck TR (1998) Statistical Assessment of Multi-Valued Diagnostic Tests. *Canadian Journal of Statistics*, 26(4):101-112.
31. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, Olopade OI, Weber BL, Rebbeck TR (1998) Characterization of an Allelic Variant in the Nifedipine-Specific Element of *CYP3A4*: Ethnic Distribution and Implications for Prostate Cancer Risk. *Human Mutation*, 12(4):289-293.
32. Felix CA, Walker AH, Lange B, Williams TM, Winick NJ, Cheung N-KV, Lovett BD, Nowell P, Blair IA, Rebbeck TR (1998) Association of *CYP3A4* Genotype with Treatment-Related Leukemia. *Proceedings of the National Academy of Sciences (USA)*, 95:13176-13181.
33. Arepally G, Rebbeck TR, Song WJ, Gilliland G, Maris JM, Poncz M (1998) Evidence for Genetic Homogeneity in a Familial Platelet Disorder with predisposition to Acute Myelogenous Leukemia. *Blood*, 92: (7) 2600-2602.
34. Margolis DJ, Halpern AC, Rebbeck T, Berwick M (1998) External validity of a melanoma prognostic model. *Archives of Dermatology*, 134:1597-1601.
35. Loh E, Rebbeck TR, Mahoney PD, Chen F, Swain JL, Holmes EW (1999) *AMPD1* Genotype Predicts Survival in Patients with Heart Failure. *Circulation*, 99:1422-1425.
36. Carroll BT, Couch FJ, Rebbeck TR, Weber BL (1999) Polymorphisms in *PTEN* in Breast Cancer Families. *American Journal of Medical Genetics*, 36:64-96.
37. Rebbeck TR, Jaffe JM, Walker AH, White DL, Wein AJ, Malkowicz SB (1999) Glutathione-S-Transferase- μ (*GSTM1*) and - θ (*GSTT1*) Genotypes in the Etiology of Prostate Cancer. *Cancer Epidemiology, Biomarkers and Prevention*, 8:283-287.

38. Rebbeck TR, Kantoff PA, Krithivas K, Godwin AK, Daly MB, Narod SA, Garber JE, Weber BL, Brown M (1999) Modification of *BRCA1*-Associated Breast Cancer Penetrance by Androgen Receptor CAG Repeat Length Variants. *American Journal of Human Genetics*, 64:1371-1377.
39. Walker AH, White DL, Jaffe JM, Kanetsky PA, Rebbeck TR (1999) Collection of Genomic DNA by Buccal Swabs for PCR-Based Biomarker Assays. *Environmental Health Perspectives*, 107(7):3-7.
40. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod S, Neuhausen S, Lynch HT, Weber BL (1999) Reduction in Breast Cancer Risk Following Bilateral Prophylactic Oophorectomy in *BRCA1* Mutation Carriers. *Journal of the National Cancer Institute*, 91(17):1475-1479.
41. Amirmani B, Walker AH, Weber BL, Rebbeck TR (1999) Response to Ando et al. Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in *CYP3A4* (letter). *Journal of the National Cancer Institute*, 91(18):1588-1590.
42. Rebbeck TR (2000) More About: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in *CYP3A4* (letter). *Journal of the National Cancer Institute*, 92(10):76.
43. Jaffe JM, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ, Malkowicz SB, Rebbeck TR (2000) Association of *SRD5A2* Genotype and Pathologic Characteristics of Prostate Tumors. *Cancer Research*, 60:1626-1630.
44. Rebbeck TR, Walker AH, Zeigler-Johnson CM, Weisburg S, Martin A-M, Nathanson KL, Wein AJ, Malkowicz SB (2000) Association of *HPC2/ELAC2* Genotypes and Prostate Cancer. *American Journal of Human Genetics*, 67:1014-1019.
45. Shih HA, Nathanson KL, Seal S, Collins N, Stratton MR, Rebbeck TR, Weber BL (2000). *BRCA1* and *BRCA2* mutations in breast cancer families with multiple primary cancers. *Clinical Cancer Research*, 6(11):4259-64.
46. Weiss MJ, Guo C, Shusterman S, Hii G, Mirensky TL, White PS, Hogarty MD, Rebbeck TR, Teare D, Urbanek M, Brodeur GM, Maris JM. (2000) Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. *Medical Pediatric Oncology*. 35(6):526-30.
47. Lovett BD, Strumberg D, Blair IA, Pang S, Burden DA, Megonigal MD, Rappaport EF, Rebbeck TR, Osheroff N, Pommier YG, Felix CA (2001) Etoposide Metabolites Enhance DNA Topoisomerase II Cleavage Near Leukemia-Associated MLL Translocation Breakpoints. *Biochemistry*, 40(5); 1159-1170.
48. Carlini EJ, Raftogianis RB, Wood, TC, Jun F, Zheng W, Rebbeck TR, Weinshilboum RM (2001) Sulfation Pharmacogenetics: *SULT1A1* and *SULT1A2* Allele Frequencies in Caucasian, Chinese, and African American Subjects. *Pharmacogenetics*, 11:57-68.
49. Kelada SN, Kardia SLR, Walker AH, Wein AJ, Malkowicz SB, Rebbeck TR (2001) The Glutathione S-Transferase- μ (*GSTM1*) and - θ (*GSTT1*) Genotypes in the Etiology of Prostate Cancer: Gene-Environment Interactions with Smoking. *Cancer Epidemiology Biomarkers and Prevention*, 9:1329-1334.
50. Turner BC, Krajewski S, Krajewski M, Takayama S, Grumbs AA, Carter D, Rebbeck TR, Haffty BG, Reed JC (2001) BAG-1: A novel biomarker predicting long-term survival in early stage breast cancer. *Journal of Clinical Oncology*, 15;19(4):992-1000.

51. Acs G, Lawton TJ, Rebbeck TR, LiVolsi VA, Zhang PJ (2001) Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications. *American Journal of Clinical Pathology*. 115(1):85-98.
52. Nathanson KL, Omaruddin R, Malkowicz SB, Rebbeck TR (2001) An intronic variant in PTEN is not Associated with Prostate Cancer Risk. *Cancer Epidemiology, Biomarkers and Prevention*, 10(3):277-278.
53. Kanetsky PA, Holmes R, Walker A, Najarian D, Swoyer J, Guerry D, Halpern A, Rebbeck TR. (2001) Interaction of glutathione S-transferase M1 and T1 genotypes and malignant melanoma. *Cancer Epidemiology Biomarkers and Prevention*, 10:509-513.
54. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, Powell SM, Rebbeck TR, Sidransky D, Gazdar AF, El-Deiry WS (2001) Nucleotide Substitution in the Ectodomain of TRAIL Receptor DR4 is Associated with Lung Cancer and head and Neck Cancer. *Clinical Cancer Research*, 7:1688-1697.
55. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen S, Godwin AK, Daly MB, Narod SA, Brunet J-S, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M (2001) Modification of *BRCA1*- and *BRCA2*-Associated Breast Cancer Risk by *AIB1* Genotype and Reproductive History, *Cancer Research*, 61:5420-5424.
56. Runnebaum IB, Wang-Gohrke S, Vesprini D, Kreienberg R, Lynch H, Moslehi R, Ghadirian P, Weber B, Godwin A, Risch H, Garber J, Lerman C, Olipade O, Foulkes W, Karlan B, Warner E, Rosen B, Rebbeck T, Tonin P, Dube M-P, , Kieback DG, Narod SA. (2001) Progesterone Receptor Variant Increases Ovarian Cancer Risk in *BRCA1* and *BRCA2* Mutation Carriers Who Were Never Exposed to Oral Contraceptives. *Pharmacogenetics*, 11(7):635-8.
57. Garte SJ, Gaspari L, Alexandrie A, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell'Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh L, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EMM, London S, Manni JJ, Maugard CM, Morita S, Nazar- Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WHM, Rannug A, Rebbeck TR, Risch A, Roelandt L, Romkes M, Ryberg D, Schoket B, Seidegard J, Shields P, Sim E, Sinnet D, Strange RC, Stucker I, Sugimura I, To-Figueras J, Vineis P, Yu M, Taioli E (2001) Metabolic Gene Polymorphism Frequencies in Control Populations. *Cancer Epidemiology, Biomarkers and Prevention*, 10(12):1239-1248.
58. Kanetsky PA, Swoyer J, Panossian S, Holmes R, Guerry D, Rebbeck TR (2002) A Polymorphism in the Agouti signal protein Gene is associated with Human Pigmentation. *American Journal of Human Genetics*, 70:770-775.
59. Shih HA, Couch FJ, Nathanson KL, Blackwood MA, Rebbeck TR, Calzone K, Stopfer J, Seal S, Stratton MR, Weber BL (2002) *BRCA1* and *BRCA2* Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic, *Journal of Clinical Oncology*, 20(4):994-9.
60. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van 't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL for The PROSE Study Group (2002) Reduction in Cancer Risk After Bilateral Prophylactic Oophorectomy in *BRCA1* and *BRCA2* Mutation Carriers. *New England Journal of Medicine*, 346:1616-1622.

61. Nathanson KL, Shugart YY, Omaruddin R, Szabo C, Goldgar D, Rebbeck TR, Weber BL (2002) CGH-targeted linkage analysis reveals a possible *BRCA1* modifier locus on chromosome 5q. *Human Molecular Genetics*, 11(11):1327-32.
62. Rebbeck TR, Kanetsky PA, Walker AH, Holmes R, Halpern AC, Schuchter LM, Elder DE, Guerry D (2002). *P* Gene as a Susceptibility Biomarker for Human Eye Color. *Cancer Epidemiology Biomarkers and Prevention*, 11(8): 782-784.
63. Aplenc R, Orudjev E, Swoyer J, Mancke B, Deitz A, Rebbeck TR (2002) Differential Bone Marrow Aspirate DNA Yields from Commercial Extraction Kits, *Leukemia*, 16(9):1865-6.
64. Acs G, Zhang PJ, Rebbeck TR, Acs P, Verma A (2002) Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma. *Cancer*, 95(5):969-981.
65. Brose MS, Rebbeck TR, Calzone KC, Stopfer, JE, Nathanson KL, Weber BL (2002) Penetrance Estimates for *BRCA1* Carriers Identified in a Cancer Risk Evaluation Program. *Journal of the National Cancer Institute*, 94(18):1365-72.
66. Merz JF, Rebbeck TR, Sankar P, Meagher EA (2002) Does the White Coat Influence Research Participation? *IRB, Ethics and Human Research*, 24(4):6-8.
67. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, MacBride S., Malkowicz SB, Ofori-Adjei D, Gueye SM, Rebbeck TR (2002) Ethnic Differences in the Frequency of Prostate Cancer Susceptibility Alleles at *SRD5A2* and *CYP3A4*. *Human Heredity*, 54(1):13-21.
68. Maris JM, Weiss MJ, Mosse Y, Hii G, Guo C, White PS, Hogarty MD, Mirensky T, Brodeur GM, Rebbeck TR, Urbanek M, Shusterman S (2002) Evidence for a Hereditary Neuroblastoma Predisposition Locus at Chromosome 16p12-13. *Cancer Research*, 62(22):6651-8.
69. Aplenc R, Zhao H, Rebbeck TR, Prokert KJ (2003) Group Sequential Methods and Sample Size Savings in Biomarker-Disease Association Studies. *Genetics*, 163(3):1215-9.
70. Martin AM, Kanetsky PA, Amirimani B, Colligon TA, Athanasiadis G, Shih HA, Gerrero MR, Calzone K, Rebbeck TR, Weber BL. (2003) Germline TP53 mutations in breast cancer families with multiple primary cancers: is TP53 a modifier of *BRCA1*? *J Med Genet.* 40(4):e34.
71. Gueye SM, Zeigler-Johnson CM, Friebe T, Spangler E, Jalloh M, MacBride S, Malkowicz SB, Rebbeck TR (2003) Clinical Characteristics of Prostate Cancer in African Americans, American Caucasians and Senegalese Men, *Urology*, 61:987-992.
72. Aplenc R, Glatfelter W, Han P, Rappaport E, La M, Cnaan A, Blackwood MA, Lange B, Rebbeck T (2003) *CYP3A* genotypes and treatment response in paediatric acute lymphoblastic leukaemia. *Br J Haematol.* 122(2):240-4.
73. Martin AM, Athanasiadis G, Greshock JD, Fisher J, Lux MP, Calzone K, Rebbeck TR, Weber B (2003) Population Frequencies of Single Nucleotide Polymorphisms (SNPs) in Immunomodulatory Genes. *Human Heredity* 55:171-178.
74. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar F, Rebbeck TR (2003) Transcriptional Activity Effects of a *CYP3A4* Promoter Variant. *Environmental and Molecular Mutagenesis*, 42(4):299-305.
75. Smits KM, Benhamou S, Garte S, Weijenberg MP, Alamanos Y, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Boffetta P, Bouchardy C, Brockmoller J, Butkiewicz D, Cascorbi I, Clapper ML, Coutelle C, Daly A, Muzi G, Dolzan V, Duzhak TG, Farker K, Golka K, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh L, Ingelman-Sundberg M, Kalina I, Kang D, Katoh T, Kihara M, Kihara M, Kim H, Kiyohara C, Kremers P, Lazarus P, Le

- Marchand L, Lechner MC, London S, Manni JJ, Maugard CM, Morgan GJ, Morita S, Nazar-Stewart V, Nedelcheva Kristensen V, Oda Y, Parl FF, Peters WHM, Rannug A, Rebbeck T, Ribeiro Pinto LF, Risch A, Romkes M, Šalagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnett D, Strange RC, Stucker I, Sugimura I, To-Figueras J, Vineis P, Yu MC, Zheng W, Pedotti P, Taioli E (2004) Association of metabolic gene polymorphisms with tobacco consumption in healthy controls, *International Journal of Cancer*, 110(2):266-70.
76. Kanetsky PA, Ge F, Guerry D, Rebbeck TR (2004) Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. *Cancer Epidemiology, Biomarkers and Prevention*, 13(5):808-819.
77. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL (2004) Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk In *BRCA1* and *BRCA2* Mutation Carriers, *Journal of Clinical Oncology*, 22(6):1055-62.
78. Wang Y, Localio R, Rebbeck TR (2004) Evaluating Bias Due to Population Stratification in Case-Control Association Studies of Admixed Populations, *Genetic Epidemiology*, 27(1):14-20.
79. Vogl FD, Taioli E, Maugard C, Zheng W, Pinto F, Ambrosone CA, Parl F, Nedelcheva-Kristensen V, Rebbeck TR, Brennan P, Boffetta P (2004) Glutathione S-transferases M1, T1 and P1 and breast cancer: a pooled analysis, *Cancer Epidemiology Biomarkers and Prevention* 13:1473-1479.
80. Deitz AC, Rothman N, Rebbeck TR, Hayes R, Chow W-H, Zheng W, Hein DW, Garcia-Closas M, (2004) Impact of Misclassification in Genotype-Exposure Interaction Studies: Example of N-acetyltransferase 2 (NAT2), Smoking and Bladder Cancer. *Cancer Epidemiology Biomarkers and Prevention*, 13(9):1543-6.
81. Huang J, Domchek SM, Brose SM, Rebbeck TR, Nathanson KL, Weber BL (2004) Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers. *Journal of Medical Genetics*, 41(11):e120.
82. Zeigler-Johnson CM, Friebel T, Walker AH, Wang Y, Spangler E, Panossian S, Patacsil M, Aplenc R, Wein AJ, Malkowicz SB, Rebbeck TR (2004) *CYP3A4*, *CYP3A5*, and *CYP3A43* Genotypes and Haplotypes in the Etiology and Severity of Prostate Cancer. *Cancer Research*, 64:8461-8467.
83. Spangler, E, Zeigler-Johnson CM, Malkowicz SB, Wein A, Rebbeck TR (2004) Association of Prostate Cancer Family History with Histopathological and Clinical Characteristics of Prostate Tumors. *International Journal of Cancer*, 113(3):471-4.
84. Begg CB, Hummer A, Mujumdar U, Armstrong BK, Krickler A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Klotz JB, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Berwick M (2004). Familial Aggregation of Melanoma Risks in a Large Population-Based Sample of Melanoma Cases. *Cancer Causes and Control*, 15(9):957-65.
85. Aplenc R, Thompson J, Han P, Glatfelter W, La M, Zhao H, Lange B, Rebbeck TR (2005) *MTHFR* Polymorphisms and therapy response in pediatric acute lymphoblastic leukemia, *Cancer Research*, 65(6):2482-7.
86. Rennert H, Zeigler-Johnson CM, Addya K, Finely MJ, Walker AH, Spangler E, Leonard DGB, Wein A, Malkowicz SB, Rebbeck TR (2005) Association of Susceptibility Alleles in *ELAC2/HPC2*, *RNASEL/HPCI1*, and *Macrophage Scavenger Receptor 1* with Prostate Cancer

- Severity in European-American and African-American Men, *Cancer Epidemiology Biomarkers and Prevention*, 14(4):949-957.
87. Colilla S, Lerman C, Shields PG, Jepson C, Rukstalis M., Berlin J, DeMichele A, Bunin G, Strom BL, Rebbeck TR (2005) Catechol-O-Methyltransferase V158M Polymorphism is Associated with Smoking Cessation in Two Independent Studies of Women, *Pharmacogenetics and Genomics*, 15(6):393-398.
88. Wang Y, Localio R, Rebbeck TR (2005) Consideration of The Minimal Number Of Unlinked Markers Required To Correct For Bias Due To Population Stratification In Candidate Gene Association Studies, *Human Heredity*, 59:165-175.
89. Landi MT, Kanetsky PA, Tsang S, Gold B, Munroe D, Rebbeck T, Swoyer J, Ter-Minassian M, Hedayati M, Grossman L, Goldstein AM, Calista D, Pfeiffer RM (2005) *MC1R*, *ASIP*, and DNA repair in sporadic and familial melanoma in a Mediterranean population, *JNCI* 97(13):998-1007.
90. DeMichele A., Aplenc R., Botbyl J., Colligan T., Wray L., Klein-Cabral M., Foulkes A, Glick J, Weber B, Stadtmauer E., Rebbeck TR (2005) Drug Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort, *Journal of Clinical Oncology*, 23(24):5552-9.
91. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, Van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, The PROSE Study Group, Eisen A, Domchek S, Armstrong K, Weber BL (2005) Effect Of Short Term Hormone Replacement Therapy On Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy In *BRCA1* And *BRCA2* Mutation Carriers. *Journal of Clinical Oncology*, *In Press*.
92. Begg CB, Orlow I, Hummer A, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SC, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M (2005) Lifetime Risk of Melanoma In *CDKN2A* Carriers In a Population-Based Sample, *JNCI*, *In Press*.
93. Shatalova EG, Walther SE, Favorova OO, Rebbeck TR, Blanchard RL (2005) Genetic polymorphisms in human *SULT1A1* and *UGT1A1* genes modify breast tumor aggressiveness, *Breast Cancer Research*, *In Press*.
94. Pierce LJ, Levin A, Rebbeck TR, Kardia S, Ben-David M, Friedman E, Solin L, Harris E, Gaffney D, Haffty B, Dawson L, Metcalfe K, Narod S, Olivotto I, Eisen A, Whelan T, Meirovitz A, Galinsky D, Olopade O, Isaacs C, Merajver S, Wong J, Garber J, Weber B (2005) Multi-Institutional 10-Year Results of Breast-Conserving Surgery and Radiotherapy in *BRCA1/2*-Associated Breast Cancer, *submitted*.
95. Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck TR, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Isaacs C, Kim-Sing C, Ainsworth P, Couch F, Garber JE, Daly M, Rosen B, Olopade O, Karlan B, Tung N, Saal HM, Weitzel J, Eng C, Sun P, Narod SA (2005) Breast Cancer Risk Following Bilateral Oophorectomy in *BRCA1* and *BRCA2* Mutation Carriers: An International Case-Control Study, *submitted*.
96. Domchek SM, Greshock J, Tweed AJ, Tigges J, Blackwood-Chirchir MA, Yang H, Nathanson KL, Stratton M, Easton D, Stopfer J, Olopade O, Rebbeck TR, Weber BL (2004) A Web-Based Prediction Model for *BRCA1* and *BRCA2* Mutations, *submitted*.

97. Wang Y, Localio R, Rebbeck TR (2005) Biases Due To Population Stratification In Epidemiological Studies of Gene-Gene Interactions, *submitted*.
98. Berwick M, Orlow I, Hummer A, Armstrong BK, Krickler A, Marrett LD, Millikan RC, Gruber SC, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Begg CB (2005) An International Population-Based Study of *CDKN2A* Prevalence and Relative Risk, *submitted*.
99. Kanetsky PA, Rebbeck TR, Hummer A, Panossian S, Begg C, Berwick M, for the GEM Study Group (2005) A population-based study of natural variation in *MC1R* and melanoma, *submitted*.
100. Millikan RC, Hummer A, Begg C, Player J, de Cotret AR, Winkel S, Mohreweiser H, Armstrong B, Krickler A, Marrett LD, Gruber SB, Anton Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck T, Busam K, From L, Mujumdar U, Berwick M, for the GEM Study Group (2005) Polymorphisms in Nucleotide Excision Repair Genes and Risk of Malignant Melanoma: the Genes Environment and Melanoma Study, *submitted*.
101. Orlow I, Begg CB, Cotignola JH, Roy P, Hummer AJ, Clas BA, Reva B, Mujumdar U, Armstrong BK, Krickler A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Busam K, From L, Berwick M for The GEM Study Group (2005) *CDKN2A* Germline Mutations in Individuals with Cutaneous Malignant Melanoma, *submitted*.
102. Iversen ES, Luedi PP, Schildkraut J, Rebbeck T, Weber B, Isaacs C, Finkelstein DM (2005) Oral Contraceptive Use as a Modifier of BRCA1 and BRCA2 Penetrance: Methods and Results from a High Risk Case Series Analysis with Independence Assessment, *submitted*.

Contributions to Peer-Reviewed Research Publications, Participation Cited but not by Authorship:

1. Narod SA, Risch H, Moslehi R, Neuhausen S, Moller P, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet JS, Easton D, and the Hereditary Ovarian Cancer Clinical Study Group (1998) Oral Contraceptive Use Reduces the Risk of Hereditary Ovarian Cancer. *New England Journal of Medicine*, 339:424-8.
2. Taioli E And The Collaborative Group On Genetic Susceptibility To Environmental Carcinogens (1999) International Collaborative Study On Genetic Susceptibility To Environmental Carcinogens. *Cancer Epidemiology, Biomarkers, and Prevention*, 8:727-728.
3. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, Kim-Sing C, Olsson H, Ainsworth P, Eisen A, Saal H, Friedman E, Olopade O, Osborne M, Weitzel J, Lynch H, Ghadirian P, Lubinski J, Sun P, Narod SA and the Hereditary Breast Cancer Clinical Study Group. (2005) Tamoxifen And Contralateral Breast Cancer In *BRCA1* And *BRCA2* Carriers: An Update, *Submitted*.

Research Publications, Non-Peer Reviewed:

1. Rebbeck TR (1986) *The Monoclonal Gammopathies: Characterization and Clinical Associations in a Hospital Population*. Baltimore: The Johns Hopkins University.
2. Rebbeck TR (1991) *Predicting Predisposition of Complex Disease Using Genetic Information: An Application to Human Hypertension*. Ann Arbor: University Microfilms International.
3. Rebbeck TR, Walker AH, Phelan CM, Godwin AK, Buetow KH, Narod SA, Garber JE, Weber BL (1997) Defining Etiologic Heterogeneity in Breast Cancer Using Genetic Biomarkers. In: Aldaz CM, Gould MN, McLachlan J, Slaga TJ (Eds) *Etiology of Breast and Gynecological Cancers*. *Progress in Clinical and Biological Research*, 396:53-62.

4. Rebbeck TR (1999) Inherited Genetic Predisposition in Breast Cancer: A Population-Based Perspective. *Cancer* 86(11 Supplement):2493-2501.
5. White DL, Rebbeck TR (1999) Using MasterAmp PCR Premixes to Optimize Analysis of High GC Content Genes: PCR Amplification of the Melanocortin-1 Receptor Gene. *Epicentre Forum*, 3:23-4.

Editorials, Reviews, Chapters, Including Participation in Committee Reports:

1. Solin LJ, Fox K, August DA, Dershaw DD, Rebbeck TR, Weber BL, Lichter A (1996) Breast Cancer. In: Hoskins WJ, Perez CA, Young RC. *Principles and Practices of Gynecologic Oncology, Second Edition*. Philadelphia: J.B. Lippincott Co, pp. 1079-1142.
2. Rogatko A, Babb J, Rebbeck TR (1997) Genetic Counseling. In: Armitage P, Colton T. *Encyclopedia of Biostatistics, Volume 2*. Chichester: John Wiley and Sons, pp. 1672-1674.
3. Rebbeck, TR (1998) Reduction of Breast or Ovarian Cancer Risk by Prophylactic Surgery in *BRCA1* or *BRCA2* Mutation Carriers. Oncolink: The University of Pennsylvania Cancer Resource; http://www.oncolink.upenn.edu/disease/breast/treat/risk_reduction.html/ Available from: The Internet. Accessed 1998, April 19.
4. Rebbeck TR (1999) Breast Cancer Risk and Risk Modification in *BRCA1* Mutation Carriers. In Perry MC (ed.) ASCO Educational Book, Alexandria, VA: ASCO, p 454-459.
5. Rebbeck TR (1999) Genetic Susceptibility to Breast Cancer: High Penetrance and Low Penetrance Factors. In Ehrlich M (Ed.) *DNA Alterations in Cancer: Genetic and Epigenetic Changes*. Natick, MA: BioTechniques Books.
6. Eisen A, Rebbeck TR, Wood WC, Weber BL (2000) Prophylactic Surgery in Women with a Hereditary Predisposition to Breast and Ovarian Cancer. *Journal of Clinical Oncology*, 18(9): 1980-1995.
7. Rebbeck TR (2000) Cancer Risk Modifying Factors in *BRCA1* Mutation Carriers, In: *Proceedings of the UICC Symposium. Familial Cancer and Prevention: Molecular Epidemiology*, J. Utsunomiya, J. Mulvihill, W. Weber, Y. Yuasa, eds. New York: John Wiley and Sons.
8. Rebbeck TR. (2000) Prophylactic oophorectomy in *BRCA1* and *BRCA2* mutation carriers. *Journal of Clinical Oncology*, 18(21 Suppl):100S-3S.
9. Rebbeck, TR (2002) Inherited Susceptibility and Prostate Cancer Risk. In: *Cellular and Molecular Toxicology Volume 14*, Vanden Heuvel JP, Perdew GH, Mattes WB, Greenlee WF, eds. New York: Elsevier Press, pp. 267-282.
10. Rebbeck, TR (2002) Inherited Predisposition and Breast Cancer: Modifiers of *BRCA1/2*-Associated Breast Cancer Risk. *Environmental and Molecular Mutagenesis*, 39(2/3): 228-234.
11. Rebbeck TR. (2002) Inherited genotype and prostate cancer outcomes. *Cancer Epidemiology, Biomarkers and Prevention*. 11(10):945-52.
12. Rebbeck, TR (2002) Prophylactic Oophorectomy in *BRCA1* and *BRCA2* Mutation Carriers. *European Journal of Cancer (Supplement)*, 38 Suppl 6:15-7.
13. Rebbeck TR (2003) Epidemiologic Approaches to Tumor Gene Identification. In: *Tumor Suppressor Genes: Methods and Protocols*, El Deiry, W, ed., Totowa, NJ: Humana Press, pp. 309-326.

14. Rebbeck TR (2004) Biomarkers of Inherited Susceptibility and Cancer. In: Buffler P, Rice J, Baan R, Bird M, Boffetta P. Mechanisms of Carcinogenesis: Contributions of Molecular Epidemiology. IARC Scientific Publication 157. Lyon: IARC Press, pp. 91-103.
15. Rebbeck TR, Ambrosone CB, Bell D, Chanock S, Hayes R, Kadlubar F, Thomas D (2003) SNP's, Haplotypes, and Cancer: Applications in Molecular Epidemiology. *Cancer Epidemiology, Biomarkers and Prevention*, 13(5):681-687.
16. Rebbeck TR, Spitz M, Wu, X (2004) Assessing Function of Genetic Variants in Candidate Gene Association Studies. *Nature Reviews Genetics*, 5(8):589-97.
17. Rebbeck TR (2004) Prophylactic Oophorectomy in Women with *BRCA1* and *BRCA2* Mutations. In: DeVita VT, Hellman S, Rosenberg SA: *Cancer: Principles and Practice of Oncology*. 18(5): 1-12.
18. Rebbeck TR, Martínez ME, Sellers TA, Shields PG, Wild CP, Potter JD (2004) Genetic Variation and Cancer: Improving the environment for publication of association studies. *Cancer Epidemiology, Biomarkers, and Prevention*, 13(12):1985-6.
19. Stephen E. Kimmel SE, Leufkens HG, Rebbeck TR (2005) Molecular Pharmacoepidemiology. In: Strom BL: *Pharmacoepidemiology*.
20. Zeigler-Johnson C, Gueye SM, Rebbeck TR (2005) Prostate Cancer in Africa. In: Ly A, Khayat D. *About Cancer In Africa*. Paris: UNESCO.
21. Potter JH, Rebbeck TR (2005) Molecular Epidemiology of Cancer. In: *Encyclopedia of Medical Genomics and Proteomics*. New York: Marcel Dekker.
22. Kanetsky PA, Rebbeck TR (2005) Low-Penetrance Genotypes, Pigmentation Phenotypes, and Melanoma Etiology. In: *From Melanocytes to Malignant Melanoma*. V. Hearing and S. Leong (Eds). Totowa NJ: Humana Press, pp. 345-363.
23. Rebbeck TR. (2005) Genetics, disparities, and prostate cancer. LDI Issue Brief. 10(7):1-4.
24. Rebbeck TR, Stopfer JE, Domchek S (2005) Commentary: Use Of Hormone Replacement Therapy After Bilateral Risk-Reducing Oophorectomy In *BRCA1* And *BRCA2* Mutation Carriers, *Hereditary Cancer in Clinical Practice, In Press*.
25. Rebbeck TR, Sankar P (2005) Ethnicity, Ancestry, and Race in Molecular Epidemiological Research, *Cancer Epidemiology, Biomarkers and Prevention, In Press*.
26. Rebbeck TR, Sankar P (2005) "Race/Ethnicity in Molecular epidemiology Studies: Is it black and white?" *Journal of Clinical Oncology, In Press*.
27. Rebbeck TR, Stopfer JE, Domchek S (2005) Bilateral Risk-Reducing Oophorectomy In *BRCA1* And *BRCA2* Mutation Carriers, *Journal of the National Comprehensive Cancer Network, In Press*.

Alternative Media:

None

Books:

None

Patents:

US Patent 6,174,684 "CYP3A4 NFSE Variant and Methods of Use Thereof".